Nursing Management
Male Reproductive Problems
1. Describe the pathophysiology, clinical manifestations, and collaborative care of benign prostatic hyperplasia.
2. Describe the nursing management of benign prostatic hyperplasia.
3. Describe the pathophysiology, clinical manifestations, and collaborative care of prostate cancer.
4. Explain the nursing management of prostate cancer.
5. Specify the pathophysiology, clinical manifestations, and nursing and collaborative management of prostatitis and problems of the penis and scrotum.
6. Explain the clinical manifestations and collaborative care of testicular cancer.
7. Describe the pathophysiology, clinical manifestations, and nursing and collaborative management of problems related to male sexual function.
8. Summarize the psychologic and emotional implications related to male reproductive problems.
Reviewed by Debra Backus, RN, PhD, CNE, NEA-BC, Associate Professor of Nursing, State University of New York, Canton, New York; and David J. Derrico, RN, MSN, Assistant Clinical Professor, University of Florida, Gainesville, Florida.
This chapter discusses problems of the male reproductive system. These involve a variety of structures, including the prostate, penis, urethra, ejaculatory duct, scrotum, testes, epididymis, ductus (vas) deferens, and rectum (Fig. 55-1).
Problems of the Prostate Gland
Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is a benign enlargement of the prostate gland. It is the most common urologic problem in male adults. About 50% of all men in their lifetime will develop BPH. Of these men, almost half of them will have bothersome lower urinary tract symptoms.1 Research is not clear about whether having BPH leads to an increased risk of developing prostate cancer.2,3
Etiology and Pathophysiology
Although the cause of BPH is not completely understood, it is thought that BPH results from hormonal changes associated with the aging process.1 One possible cause is excessive accumulation of dihydroxytestosterone (DHT) (the principal intraprostatic androgen) in the prostate cells. This can stimulate cell growth and an overgrowth of prostate tissue. Older men have a decrease in the blood’s testosterone level, but continue to produce and accumulate high levels of DHT in the prostate.
Typically BPH develops in the inner part of the prostate. (Prostate cancer is most likely to develop in the outer part.) This enlargement gradually compresses the urethra, eventually leading to partial or complete obstruction (Fig. 55-2). The compression of the urethra ultimately leads to the development of clinical symptoms. There is no direct relationship between the size of the prostate and the severity of symptoms or degree of obstruction. The location of the enlargement is most significant in the development of obstructive symptoms (Fig. 55-3). For example, it is possible for mild hyperplasia to cause severe obstruction, or for extreme hyperplasia to cause few obstructive symptoms.

Risk factors for BPH include aging, obesity (in particular increased waist circumference), lack of physical activity, alcohol consumption, erectile dysfunction, smoking, and diabetes.4 A positive family history of BPH in first-degree relatives may also be a risk factor.
Clinical Manifestations
Manifestations of BPH are mainly associated with symptoms of the lower urinary tract.5 The patient’s symptoms are usually gradual in onset and may not be noticed until prostatic enlargement has been present for some time. Early symptoms are often minimal because the bladder can compensate for a small amount of resistance to urine flow. The symptoms gradually worsen as the degree of urethral obstruction increases.
Symptoms can be divided into two groups: irritative and obstructive. Irritative symptoms, which include nocturia, urinary frequency, urgency, dysuria, bladder pain, and incontinence, are associated with inflammation or infection. Nocturia is often the first symptom that the patient notices.5
The American Urological Association (AUA) symptom index for BPH (Table 55-1) is a widely used tool to assess voiding symptoms associated with obstruction. Although this tool is not diagnostic, it helps determine the extent of symptoms.6 Higher scores on this tool indicate greater symptom severity.
TABLE 55-1
AUA SYMPTOM INDEX TO DETERMINE SEVERITY OF PROSTATIC PROBLEMS
AUA Symptom Score* (circle one number on each line) | ||||||
Questions | Not At All | Less Than 1 Time in 5 | Less Than Half the Time | About Half the Time | More Than Half the Time | Almost Always |
Over the past month | ||||||
1. How often do you have the sensation that your bladder is not completely empty after you finish urinating? | 0 | 1 | 2 | 3 | 4 | 5 |
2. How often do you have to urinate again, less than 2 hr after you finish urinating? | 0 | 1 | 2 | 3 | 4 | 5 |
3. How often do you stop and start again several times when you urinate? | 0 | 1 | 2 | 3 | 4 | 5 |
4. How often do you find it difficult to postpone urination? | 0 | 1 | 2 | 3 | 4 | 5 |
5. How often do you have a weak urinary stream? | 0 | 1 | 2 | 3 | 4 | 5 |
6. How often do you have to push or strain to begin urination? | 0 | 1 | 2 | 3 | 4 | 5 |
7. How many times do you usually get up to urinate from the time you go to bed at night until the time you get up in the morning? | 0 (None) | 1 (1 time) | 2 (2 times) | 3 (3 times) | 4 (4 times) | 5 (5 times or more) |
Sum of circled numbers (AUA Symptom Score): _____* |
AUA, American Urological Association.
*Score is interpreted as follows: 0-7, mild; 8-19, moderate; 20-35, severe.
Source: Barry MJ, Fowler FJ, O’Leary MP, et al: The American Urological Association symptom index for benign prostatic hyperplasia, J Urol 148:1549, 1992. Used with permission.
Complications
Complications of urinary obstruction are relatively uncommon in BPH. Acute urinary retention is a complication that is manifested by the sudden and painful inability to urinate. Treatment involves the insertion of a catheter to drain the bladder. Surgery may also be indicated.
Another complication is urinary tract infection (UTI) and potentially sepsis secondary to UTI. Incomplete bladder emptying (associated with partial obstruction) results in residual urine, which provides a favorable environment for bacterial growth. Calculi may develop in the bladder because of the alkalinization of the residual urine. Bladder stones are more common in men with BPH, although the risk of renal calculi is not significantly increased. Additional complications include renal failure caused by hydronephrosis (distention of pelvis and calyces of kidney by urine that cannot flow through the ureter to the bladder), pyelonephritis, and bladder damage if treatment for acute urinary retention is delayed.
Diagnostic Studies
The primary methods used to diagnose BPH include a history and physical examination. (Diagnostic studies are outlined in Table 55-2.) The prostate can be palpated by digital rectal examination (DRE) to estimate its size, symmetry, and consistency. In BPH, the prostate is symmetrically enlarged, firm, and smooth.
TABLE 55-2
COLLABORATIVE CAREBenign Prostatic Hyperplasia
Diagnostic |
Collaborative Therapy |
Active Surveillance |
Drug Therapy |
Minimally Invasive Therapy* |
Invasive (Surgery) Therapy* |
A prostate-specific antigen (PSA) blood test may be done to rule out prostate cancer. However, PSA levels may be slightly elevated in patients with BPH. Serum creatinine levels may be ordered to rule out renal insufficiency. Because symptoms of BPH are similar to those of a neurogenic bladder, a neurologic examination may also be performed.
In patients with an abnormal DRE and elevated PSA, a transrectal ultrasound (TRUS) scan is typically indicated. This examination allows for accurate assessment of prostate size and is helpful in differentiating BPH from prostate cancer. Biopsies can be taken during the ultrasound procedure. Uroflowmetry, a study that measures the volume of urine expelled from the bladder per second, is helpful in determining the extent of urethral blockage and thus the type of treatment needed. Postvoid residual urine volume is often measured to determine the degree of urine flow obstruction. Cystoscopy, a procedure allowing internal visualization of the urethra and bladder, is performed if the diagnosis is uncertain and in patients scheduled for prostatectomy.
Collaborative Care
The goals of collaborative care are to (1) restore bladder drainage, (2) relieve the patient’s symptoms, and (3) prevent or treat the complications of BPH. Treatment is generally based on the degree to which the symptoms bother the patient or the presence of complications, rather than the size of the prostate. Alternatives to surgical intervention for some patients now include drug therapy and minimally invasive procedures.
The most conservative treatment that may be recommended for some patients with BPH is referred to as active surveillance, or watchful waiting.7 When the patient has no symptoms or only mild ones (AUA symptom scores of 0 to 7), a wait-and-see approach is taken. Because some patients have symptoms that disappear, a conservative approach has value. Making dietary changes (decreasing intake of caffeine, artificial sweeteners, and spicy or acidic foods), avoiding medications such as decongestants and anticholinergics, and restricting evening fluid intake may improve symptoms.
Drug Therapy.
Drugs that have been used to treat BPH with variable degrees of success include 5α-reductase inhibitors and α-adrenergic receptor blockers. Combination therapy using both types of these drugs has been shown to be more effective in reducing symptoms than using one drug alone.
5α-Reductase Inhibitors.
These drugs work by reducing the size of the prostate gland. Finasteride (Proscar) blocks the enzyme 5α-reductase, which is necessary for the conversion of testosterone to DHT, the principal intraprostatic androgen. This drug results in regression of hyperplastic tissue through suppression of androgens. Finasteride is an appropriate treatment option for individuals who have a moderate to severe symptom score on the AUA symptom index (see Table 55-1). Although more than 50% of men who are treated with the drug show symptom improvement, it takes about 6 months to be effective. Furthermore, the drug must be taken on a continuous basis to maintain therapeutic results. Serum PSA levels are decreased by almost 50% when taking finasteride. Therefore PSA levels should be doubled when comparing the patient’s current levels to premedication levels.
In addition to decreasing the symptoms of BPH, finasteride, dutasteride, and Jalyn (finasteride plus tamsulosin) may also lower the risk of prostate cancer.8 However, the use of these drugs in prevention of prostate cancer has not been advised because of the increased risk of developing aggressive prostate cancer. Patients with an increased PSA level while taking these medications should be referred to their health care provider. The need for regular prostate cancer screening should also be discussed with the provider.
α-Adrenergic Receptor Blockers.
α-Adrenergic receptor blockers are another drug treatment option for BPH. These agents selectively block α1-adrenergic receptors, which are abundant in the prostate and are increased in hyperplastic prostate tissue. Although α-adrenergic blockers are more commonly used for treatment of hypertension, these drugs promote smooth muscle relaxation in the prostate, facilitating urinary flow through the urethra. These agents demonstrate a 50% to 60% efficacy in improvement of symptoms, which occurs within 2 to 3 weeks.
Several α-adrenergic blockers are currently in use, including silodosin (Rapaflo), alfuzosin (Uroxatral), doxazosin (Cardura), prazosin (Minipress), terazosin (Hytrin), and tamsulosin (Flomax). Note that although these drugs offer symptomatic relief of BPH, they do not treat hyperplasia.
Herbal Therapy.
Herbal extracts have been used in the management of lower urinary symptoms associated with BPH. In particular, some patients take plant extracts such as saw palmetto (Serenoa repens). However, research indicates that saw palmetto has no benefit over a placebo.10,11 In a limited number of small trials, herbal preparations such as saxifrage, beta-sitosterol, Pygeum africanum, and Cernilton have shown some success in reducing the symptoms of BPH. Advise patients to tell their health care provider about all herbal supplements that they use.
Minimally Invasive Therapy.
Minimally invasive therapies are becoming more common as an alternative to watchful waiting and invasive treatment (Table 55-3). They generally do not require hospitalization or catheterization and are associated with few adverse events. Many minimally invasive therapies have outcomes comparable to those of invasive techniques.12
TABLE 55-3
TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA
Description | Advantages | Disadvantages |
Minimally Invasive | ||
Transurethral Microwave Thermotherapy (TUMT) | ||
Use of microwave radiating heat to produce coagulative necrosis of the prostate. | Outpatient procedureErectile dysfunction, urinary incontinence, and retrograde ejaculation are rare | Potential for damage to surrounding tissueUrinary catheter needed after procedure |
Transurethral Needle Ablation (TUNA) | ||
Low-wave radiofrequency used to heat the prostate, causing necrosis. | Outpatient procedureErectile dysfunction, urinary incontinence, and retrograde ejaculation are rarePrecise delivery of heat to desired areaVery little pain experienced | Urinary retention commonIrritative voiding symptomsHematuria |
Laser Prostatectomy | ||
Procedure uses a laser beam to cut or destroy part of the prostate. Different techniques are available: | Short procedureComparable results to TURPMinimal bleedingFast recovery timeRapid symptom improvementVery effective | Catheter (up to 7 days) needed after procedure due to edema and urinary retentionDelayed sloughing of tissueTakes several weeks to reach optimal effectRetrograde ejaculation |
Transurethral Electrovaporization of Prostate (TUVP) | ||
Electrosurgical vaporization and desiccation are used together to destroy prostatic tissue. | Minimal risksMinimal bleeding and sloughing | Retrograde ejaculationIntermittent hematuria |
Intraprostatic Urethral Stents | ||
Insertion of self-expandable metallic stent into the urethra where enlarged area of prostate occurs. | Safe and effectiveLow risk | Stent may moveLong-term effect is unknown |
Invasive (Surgery) | ||
Transurethral Resection of Prostate (TURP) | ||
Use of excision and cauterization to remove prostate tissue cystoscopically. Remains the standard for treatment of BPH. | Erectile dysfunction unlikely | BleedingRetrograde ejaculation |
Transurethral Incision of Prostate (TUIP) | ||
Involves transurethral incisions into prostatic tissue to relieve obstruction. Effective for men with small to moderate prostates. | Outpatient procedureMinimal complicationsLow occurrence of erectile dysfunction or retrograde ejaculation | Urinary catheter needed after procedure |
Open Prostatectomy | ||
Surgery of choice for men with large prostates, bladder damage, or other complicating factors. Involves external incision with two possible approaches (see Fig. 55-6). | Complete visualization of prostate and surrounding tissue | Erectile dysfunctionBleedingPostoperative painRisk of infection |
Transurethral Microwave Thermotherapy.
Transurethral microwave thermotherapy (TUMT) is an outpatient procedure that involves the delivery of microwaves directly to the prostate through a transurethral probe to raise the temperature of the prostate tissue to about 113° F (45° C). The heat causes death of tissue, thus relieving the obstruction. A rectal temperature probe is used during the procedure to ensure that the temperature is kept below 110° F (43.5° C) to prevent rectal tissue damage. The procedure takes about 90 minutes.
Postoperative urinary retention is a common complication. Thus the patient is generally sent home with an indwelling catheter for 2 to 7 days to maintain urinary flow and to facilitate the passing of small clots or necrotic tissue. Antibiotics, pain medication, and bladder antispasmodic medications are used to treat and prevent postprocedure problems. The procedure is not appropriate for men with rectal problems. Anticoagulant therapy should be stopped 10 days before treatment. Mild side effects include occasional problems of bladder spasm, hematuria, dysuria, and retention.
Transurethral Needle Ablation.
Transurethral needle ablation (TUNA) is another procedure that increases the temperature of prostate tissue, thus causing localized necrosis. TUNA differs from TUMT in that low-wave radiofrequency is used to heat the prostate. Only prostate tissue in direct contact with the needle is affected, thus allowing greater precision in removal of the target tissue. The extent of tissue removed by this process is determined by the amount of tissue contact (needle length), amount of energy delivered, and duration of treatment. The majority of the patients undergoing TUNA have an improvement in symptoms.
This procedure is performed in an outpatient unit or physician’s office using local anesthesia and IV or oral sedation. The TUNA procedure lasts approximately 30 minutes. The patient typically experiences little pain with an early return to regular activities. Complications include urinary retention, UTI, and irritative voiding symptoms (e.g., frequency, urgency, dysuria). Some patients require a urinary catheter for a short time. Patients often have hematuria for up to a week.
Laser Prostatectomy.
The use of laser therapy through visual or ultrasound guidance is an effective alternative to transurethral resection of the prostate (TURP) in treating BPH. The laser beam is delivered transurethrally through a fiber instrument and is used for cutting, coagulation, and vaporization of prostatic tissue. There are a variety of laser procedures using different sources, wavelengths, and delivery systems. Retreatment rates are comparable to those of a TURP.13
Contact laser techniques involve the direct contact of the laser with the prostate tissue, producing an immediate vaporization of the tissue. Blood vessels near the laser tip are immediately cauterized. Thus bleeding during the procedure is rare. A three-way catheter with slow-drip irrigation is placed immediately after the procedure for a short time. Typically the catheter is removed within 6 to 8 hours after the procedure. Advantages of this procedure over TURP include minimal bleeding both during and after the procedure, faster recovery time, and ability to perform the surgery on patients taking anticoagulants.
Photovaporization of the prostate (PVP) uses a high-power green laser light to vaporize prostate tissue. Improvements in urine flow and symptoms are almost immediate after the procedure. Bleeding is minimal, and a catheter is usually inserted for 24 to 48 hours afterward. PVP works well for larger prostate glands.
Another approach to laser prostatectomy is interstitial laser coagulation (ILC). The prostate is viewed through a cystoscope. A laser is used to quickly treat precise areas of the enlarged prostate by placement of interstitial light guides directly into the prostate tissue.
Intraprostatic Urethral Stents.
Symptoms from obstruction in patients who are poor surgical candidates can be relieved with intraprostatic urethral stents. The stents are placed directly into the prostatic tissue. Complications include chronic pain, infection, and encrustation. The long-term effects are not known.
Invasive Therapy (Surgery).
Invasive treatment of symptomatic BPH involves surgery. The choice of the treatment approach depends on the size and location of the prostatic enlargement and patient factors such as age and surgical risk. Invasive treatments are summarized in Table 55-3.
Transurethral Resection of the Prostate.
Transurethral resection of the prostate (TURP) is a surgical procedure involving the removal of prostate tissue using a resectoscope inserted through the urethra. TURP has long been considered the gold standard for surgical treatments of obstructing BPH. Although this procedure remains the most common operation performed, the number of TURP procedures done in recent years has declined due to the development of less invasive technologies.12
TURP is performed under a spinal or general anesthetic and requires a 1- to 2-day hospital stay. No external surgical incision is made. A resectoscope is inserted through the urethra to excise and cauterize obstructing prostatic tissue (Fig. 55-4). A large three-way indwelling catheter with a 30-mL balloon is inserted into the bladder after the procedure to provide hemostasis and to facilitate urinary drainage. The bladder is irrigated, either continuously or intermittently, usually for the first 24 hours to prevent obstruction from mucus and blood clots.

The outcome for 80% to 90% of patients is excellent, with marked improvements in symptoms and urinary flow rates. Quality of life is also improved. TURP is a surgical procedure with a relatively low risk. Postoperative complications include bleeding, clot retention, and dilutional hyponatremia associated with irrigation. Because bleeding is a common complication, patients taking aspirin, warfarin (Coumadin), or other anticoagulants must discontinue these medications several days before surgery.
Transurethral Incision of the Prostate.
Transurethral incision of the prostate (TUIP) is a surgical procedure done under local anesthesia for men with moderate to severe symptoms. Several small incisions are made into the prostate gland to expand the urethra, which relieves pressure on the urethra and improves urine flow. TUIP is an option for patients with a small or moderately enlarged prostate gland. TUIP has similar patient outcomes to TURP in relieving symptoms.
Nursing Management Benign Prostatic Hyperplasia
Because you will be most directly involved in care of patients with BPH having invasive therapies, the focus of nursing management in this section is on preoperative and postoperative care.
Nursing Assessment
Subjective and objective data that should be obtained from a patient with BPH are presented in Table 55-4.
TABLE 55-4
NURSING ASSESSMENTBenign Prostatic Hyperplasia
Subjective Data
Important Health Information
Medications: Estrogen or testosterone supplementation
Surgery or other treatments: Previous treatment for BPH
Functional Health Patterns
Health perception–health management: Knowledge of the condition
Nutritional-metabolic: Voluntary fluid restriction
Elimination: Urinary urgency, diminution in caliber and force of urinary stream; hesitancy in initiating voiding; postvoid dribbling; urinary retention; incontinence
Sleep: Nocturia
Cognitive-perceptual: Dysuria, sensation of incomplete voiding; bladder discomfort
Sexuality-reproductive: Anxiety about sexual dysfunction
Objective Data
General
Older adult male
Urinary
Distended bladder on palpation; smooth, firm, elastic enlargement of prostate on rectal examination
Possible Diagnostic Findings
Enlarged prostate on ultrasonography; vesicle neck obstruction on cystoscopy; residual urine with postvoiding catheterization; white blood cells, bacteria, or microscopic hematuria with infection; ↑ serum creatinine levels with renal involvement
Nursing Diagnoses
Nursing diagnoses for the patient with BPH preoperatively may include, but are not limited to, the following:
• Acute pain related to bladder distention secondary to enlarged prostate
• Risk for infection related to an indwelling catheter, urinary stasis, or environmental pathogens
Nursing diagnoses for the patient with BPH who has invasive therapy (surgery) are presented in eNursing Care Plan 55-1 (available on the website for this chapter).
Planning
The overall preoperative goals for the patient having invasive procedures are to have (1) restoration of urinary drainage; (2) treatment of any UTI; and (3) understanding of the upcoming procedure, implications for sexual function, and urinary control. The overall postoperative goals are to have (1) no complications, (2) restoration of urinary control, (3) complete bladder emptying, and (4) satisfying sexual expression.
Nursing Implementation
Health Promotion.
The cause of BPH is largely attributed to the aging process.14 Health promotion focuses on early detection and treatment. The American Cancer Society, along with the AUA, recommends a yearly medical history and DRE for men over 50 years of age in an effort to detect prostate problems early. When symptoms of prostatic hyperplasia are present, further diagnostic screening may be necessary (see Table 55-2).
Advise patients with obstructive symptoms to urinate every 2 to 3 hours and when they first feeling the urge. This will minimize urinary stasis and acute urinary retention. Fluid intake should be maintained at a normal level to avoid dehydration or fluid overload. The patient may believe that if he restricts his fluid intake, symptoms will be less severe, but this only increases the chances of an infection. However, if the patient increases his intake too rapidly, bladder distention can develop because of the prostatic obstruction.
Acute Intervention.
The following discussion focuses on preoperative and postoperative care for the patient undergoing a TURP.
Preoperative Care.
Urinary drainage must be restored before surgery. Prostatic obstruction may result in acute retention or inability to void. A urethral catheter such as a coudé (curved-tip) catheter may be needed to restore drainage. In many health care settings, 10 mL of sterile 2% lidocaine gel is injected into the urethra before insertion of the catheter. The lidocaine gel not only acts as a lubricant, but also provides local anesthesia and helps open the urethral lumen. If a sizable obstruction of the urethra exists, the urologist may insert a filiform catheter with sufficient rigidity to pass the obstruction. Aseptic technique is important at all times to avoid introducing bacteria into the bladder. (Urinary catheters are discussed in Chapter 46.)
Patients are often concerned about the impact of the impending surgery on sexual function. Provide an opportunity for the patient and the partner to express their concerns. Inform the patient that surgery may affect sexual function. The ejaculate may be decreased in amount or be totally absent. Most types of prostatic surgery result in some degree of retrograde ejaculation. This may decrease orgasmic sensations felt during ejaculation. Retrograde ejaculation is not harmful because the semen is eliminated during the next urination.
Postoperative Care.
The main complications after surgery are hemorrhage, bladder spasms, urinary incontinence, and infection. The plan of care should be adjusted to the type of surgery, the reasons for surgery, and the patient’s response to surgery.
After surgery the patient will have a standard catheter or a triple-lumen catheter. Bladder irrigation is typically done to remove clotted blood from the bladder and ensure drainage of urine. The bladder is irrigated either manually on an intermittent basis or more commonly as continuous bladder irrigation (CBI) with sterile normal saline solution or another prescribed solution. If the bladder is manually irrigated (if ordered), instill 50 mL of irrigating solution and then withdraw with a syringe to remove clots that may be in the bladder and catheter. Painful bladder spasms often occur as a result of manual irrigation.
With CBI, irrigating solution is continuously infused and drained from the bladder. The rate of infusion is based on the color of drainage. Ideally the urine drainage should be light pink without clots. Continuously monitor the inflow and outflow of the irrigant. If outflow is less than inflow, assess the catheter patency for kinks or clots. If the outflow is blocked and patency cannot be reestablished by manual irrigation, stop the CBI and notify the physician.
Use careful aseptic technique when irrigating the bladder because bacteria can easily be introduced into the urinary tract. To prevent urethral irritation and minimize the risk of bladder infection, secure the catheter to the leg with tape or a catheter strap. The catheter should be connected to a closed-drainage system. Do not disconnect unless it is being removed, changed, or irrigated. Proper care of the catheter is important. On a daily basis, cleanse the secretions that accumulate around the meatus with soap and water.
Blood clots are expected after prostate surgery for the first 24 to 36 hours. However, large amounts of bright red blood in the urine can indicate hemorrhage. Postoperative hemorrhage may occur from displacement of the catheter, dislodgment of a large clot, or increases in abdominal pressure.
Release or displacement of the catheter dislodges the balloon that provides counterpressure on the operative site. Traction on the catheter may be applied to provide counterpressure (tamponade) on the bleeding site in the prostate, thereby decreasing bleeding. Such traction can result in local necrosis if pressure is applied for too long. Therefore pressure should be relieved on a scheduled basis by qualified personnel. Activities that increase abdominal pressure, such as sitting or walking for prolonged periods and straining to have a bowel movement (Valsalva maneuver), should be avoided in the postoperative recovery period.
Bladder spasms are a distressing complication for the patient after transurethral procedures. They occur as a result of irritation of the bladder mucosa from the insertion of the resectoscope, presence of a catheter, or clots leading to obstruction of the catheter. Instruct the patient not to urinate around the catheter because this increases the likelihood of spasm. If bladder spasms develop, check the catheter for clots. If present, remove the clots by irrigation so that urine can flow freely. Belladonna and opium suppositories or other antispasmodics (e.g., oxybutynin [Ditropan]), along with relaxation techniques, are used to relieve the pain and decrease spasm.
The catheter is often removed 2 to 4 days after surgery. The patient should urinate within 6 hours after catheter removal. If he cannot, reinsert a catheter for a day or two. If the problem continues, instruct the patient to perform clean intermittent self-catheterization (see Chapter 46).
Sphincter tone may be poor immediately after catheter removal, resulting in urinary incontinence or dribbling. This is a common but distressing situation for the patient. Sphincter tone can be strengthened by having the patient practice Kegel exercises (pelvic floor muscle technique) 10 to 20 times per hour while awake. (Kegel exercises are discussed in Table 46-19.) Encourage the patient to practice starting and stopping the stream several times during urination. This facilitates learning the pelvic floor exercises.
You can also instruct the patient to use a penile clamp, a condom catheter, or incontinence pads or briefs to avoid embarrassment from dribbling. In severe cases, an occlusive cuff that serves as an artificial sphincter can be surgically implanted to restore continence. Assist the patient in finding ways to manage the problem that allow him to continue socializing and interacting with others.
Observe the patient for signs of postoperative infection. If an external wound is present (from an open prostatectomy), assess the area for redness, heat, swelling, and purulent drainage. Special care must be taken if a perineal incision is present because of the proximity of the anus. Avoid rectal procedures, such as taking rectal temperatures and administering enemas. The insertion of well-lubricated belladonna and opium suppositories is acceptable.
Dietary intervention and stool softeners are important in the postoperative period to prevent the patient from straining while having bowel movements. Straining increases the intraabdominal pressure, which can lead to bleeding at the operative site. A diet high in fiber facilitates the passage of stool.
Ambulatory and Home Care.
Discharge planning and home care issues are important aspects of care after prostate surgery. Instructions include (1) caring for an indwelling catheter (if one is left in place); (2) managing urinary incontinence; (3) maintaining adequate oral fluid intake; (4) observing for signs and symptoms of urinary tract and wound infection; (5) preventing constipation; (6) avoiding heavy lifting (more than 10 lb [4.5 kg]); and (7) refraining from driving or intercourse after surgery as directed by the physician.
The patient may experience a change in sexual function after surgery. Many men experience retrograde ejaculation because of trauma to the internal urethral sphincter. Semen is discharged into the bladder at orgasm and may produce cloudy urine when the patient urinates after orgasm. ED may occur if the nerves are cut or damaged during surgery. The patient may experience anxiety over the change because of a perceived loss of his sex role, self-esteem, or quality of sexual interaction with his partner.
Discuss these changes with the patient and his partner and allow them to ask questions and express their concerns. Sexual counseling and treatment options may be necessary if ED becomes a chronic or permanent problem. (ED is discussed later in this chapter.)
Point out that although some patients experience concerns regarding change in sexual function, this is not a universal concern. Recovery depends on the type of surgery performed and the interval of time between when symptoms first appeared and the date of surgery. It may take up to 1 year for complete sexual function to return.
The bladder may take up to 2 months to return to its normal capacity. Instruct the patient to drink at least 2 to 3 L of fluid per day and urinate every 2 to 3 hours to flush the urinary tract. Teach the patient to avoid or limit the amounts of bladder irritants such as caffeine products, citrus juices, and alcohol. Because the patient may experience incontinence or dribbling, he may incorrectly believe that decreasing fluid intake will relieve this problem.
Urethral strictures may result from instrumentation or catheterization. Treatment may include teaching the patient intermittent clean self-catheterization or having a urethral dilation.
Advise the patient to continue having a yearly DRE if he has had any procedure other than complete removal of the prostate. Hyperplasia or cancer can occur in the remaining prostatic tissue.
Prostate Cancer
Prostate cancer is a malignant tumor of the prostate gland. It is estimated that 241,740 new cases of prostate cancer are diagnosed and 28,170 men die annually from the disease in the United States.15 One of every six men will develop prostate cancer at some point during his life. Prostate cancer is the most common cancer among men, excluding skin cancer. It is the second leading cause of cancer death in men (exceeded only by lung cancer). The majority (more than 60%) of cases occur in men over age 65. However, many cases occur in younger men who sometimes have a more aggressive type of cancer. Almost 2.8 million men in the United States are survivors of prostate cancer.16
Etiology and Pathophysiology
Prostate cancer is an androgen-dependent adenocarcinoma that is usually slow growing. It can spread by three routes: direct extension, through the lymph system, or through the bloodstream. Spread by direct extension involves the seminal vesicles, urethral mucosa, bladder wall, and external sphincter. The cancer later spreads through the lymphatic system to the regional lymph nodes. The bloodstream seems to be the mode of spread to pelvic bones, head of the femur, lower lumbar spine, liver, and lungs.
Age, ethnicity, and family history are known risk factors for prostate cancer. (Additional information on ethnicity is presented in the Cultural & Ethnic Health Disparities box on this page.) The incidence of prostate cancer rises markedly after age 50 with a median age at diagnosis of 67 years old.16 The incidence of prostate cancer worldwide is higher in African Americans than in any other ethnic group (except Jamaican men of African descent).15 The reasons for the higher rate are unknown. In addition, African American men are likely to have more aggressive tumors at diagnosis and have higher mortality rates from prostate cancer. Differences in survival may be due to body composition, dietary factors, and endogenous hormones.

Full access? Get Clinical Tree

